Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide


CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc., (Alphageneron) signed an Exclusive License Agreement with Multimmune GmbH, of Munich, Germany, (Multimmune) on October 1st, 2020, for its clinical stage autologous Natural Killer (“NK”) cell therapy and companion diagnostic platform, for all fields worldwide.

Read the original:
Alphageneron Pharmaceuticals Signed Exclusive License Agreement With Multimmune GmbH For Natural Killer Cell Platform Therapy Worldwide

Related Posts